BioCryst Pharmaceuticals (STU:BO1) ROCE % : -1.90% (As of Dec. 2024)

View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioCryst Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2024 was -1.90%.

BioCryst Pharmaceuticals ROCE % Historical Data

The historical data trend for BioCryst Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals ROCE % Chart

BioCryst Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-105.24

-35.15

-32.34

-28.62

3.39

BioCryst Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-38.17	-11.78	14.22	13.16	-1.90

BioCryst Pharmaceuticals ROCE % Calculation

BioCryst Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	11.042	/	( ( (474.052 - 137.539)	+	(468.351 - 153.167) )	/ 2 )
	=	11.042	/	( (336.513	+	315.184)	/ 2 )
	=	11.042	/	325.8485
	=	3.39 %

BioCryst Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-5.892	/	( ( (442.62 - 138.364)	+	(468.351 - 153.167) )	/ 2 )
	=	-5.892	/	( ( 304.256	+	315.184 )	/ 2 )
	=	-5.892	/	309.72
	=	-1.90 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

BioCryst Pharmaceuticals (STU:BO1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioCryst Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCryst Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (STU:BO1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BCRX:USA

Address

4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website

https://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BioCryst Pharmaceuticals Headlines

No Headlines